Flexion Therapeutics Inc (FLXN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Flexion Therapeutics Inc (FLXN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9840
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Flexion Therapeutics Inc (Flexion) develops and commercializes pain therapies. The company’s pipeline is focused on indications that includes osteoarthritis knee pain (repeat administration), osteoarthritis knee synovial inflammation, bilateral knee osteoarthritis pain shoulder and hip osteoarthritis pain and inflammatory conditions. The company’s marketed product includes Zilretta which is the first and only extended-release, intra-articular therapy for patients confronting osteoarthritis-related knee pain. Flexion employs its proprietary microsphere technology to combine TA with a PLGA matrix for formulating Zilretta. It offers anti-inflammatory and analgesic therapies for osteoarthritis. Flexion is headquartered in Burlington, Massachusetts, the US.

Flexion Therapeutics Inc (FLXN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Flexion Therapeutics Raises USD20 Million In Series B Financing 11
Flexion Therapeutics Raises Additional US$13 Million In Series A Financing 12
Licensing Agreements 13
Flexion Therapeutics to Acquire Rights to GQ-203 13
Flexion Therapeutics Enters into Licensing Agreement with Southwest Research Institute 14
Equity Offering 15
Flexion Therapeutics Prices Public Offering of Shares for USD122.4 Million 15
Flexion Therapeutics Raises USD74.5 Million in Public Offering of Shares 17
Flexion Therapeutics Raises USD82.6 Million in Public Offering of Shares 19
Flexion Therapeutics Raises USD98.5 Million in Public Offering of Shares 21
Flexion Therapeutics Completes IPO For US$74.7 Million 23
Debt Offering 25
Flexion Therapeutics Raises USD201.3 Million in Private Placement of 3.375% Notes Due 2024 25
Acquisition 26
Sanofi May Acquire Flexion Therapeutics for up to USD1 Billion 26
Flexion Therapeutics Inc – Key Competitors 27
Flexion Therapeutics Inc – Key Employees 28
Flexion Therapeutics Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Nov 07, 2018: Flexion Therapeutics reports third-quarter 2018 financial results and recent business highlights 30
Aug 07, 2018: Flexion Therapeutics reports second-quarter 2018 financial results and recent business highlights 32
May 08, 2018: Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights 34
Mar 08, 2018: Flexion Therapeutics Reports Full Year 2017 Financial Results 36
Nov 06, 2017: Flexion Therapeutics Reports Third-Quarter 2017 Financial Results and Recent Business Highlights 37
Aug 08, 2017: Flexion Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights 38
May 04, 2017: Flexion Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights 39
Mar 09, 2017: Flexion Reports Year-End 2016 Financial Results 40
Corporate Communications 41
May 07, 2018: Flexion Therapeutics Appoints David Arkowitz As Chief Financial Officer 41
Dec 12, 2017: Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as CMO 42
Dec 11, 2017: Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer 43
Jun 28, 2017: Flexion Therapeutics appoints new senior vice president, general counsel and secretary 44
Apr 07, 2017: Flexion Therapeutics Announces Appointment of Yamo Deniz, MD, as Chief Medical Officer 45
Product News 46
07/31/2018: New gene therapy treatment for osteoarthritis 46
07/10/2017: Flexion Therapeutics: Update on FX101 47
Clinical Trials 48
Apr 29, 2018: Flexion Therapeutics Announces Presentation of Positive FX201 Data at the Osteoarthritis Research Society International World Congress 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Flexion Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Flexion Therapeutics Raises USD20 Million In Series B Financing 11
Flexion Therapeutics Raises Additional US$13 Million In Series A Financing 12
Flexion Therapeutics to Acquire Rights to GQ-203 13
Flexion Therapeutics Enters into Licensing Agreement with Southwest Research Institute 14
Flexion Therapeutics Prices Public Offering of Shares for USD122.4 Million 15
Flexion Therapeutics Raises USD74.5 Million in Public Offering of Shares 17
Flexion Therapeutics Raises USD82.6 Million in Public Offering of Shares 19
Flexion Therapeutics Raises USD98.5 Million in Public Offering of Shares 21
Flexion Therapeutics Completes IPO For US$74.7 Million 23
Flexion Therapeutics Raises USD201.3 Million in Private Placement of 3.375% Notes Due 2024 25
Sanofi May Acquire Flexion Therapeutics for up to USD1 Billion 26
Flexion Therapeutics Inc, Key Competitors 27
Flexion Therapeutics Inc, Key Employees 28
Flexion Therapeutics Inc, Subsidiaries 29

List of Figures
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Flexion Therapeutics Inc (FLXN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Swadeshi Industrial Works Plc:企業の戦略・SWOT・財務情報
    Swadeshi Industrial Works Plc - Strategy, SWOT and Corporate Finance Report Summary Swadeshi Industrial Works Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • U.S. Energy Corp Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    U.S. Energy Corp Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary U.S. Energy Corp (US Energy) is an oil and gas company that offers exploration, development and production of oil and natural gas properties. The company provides maintenance of mineral properties. It o …
  • Spine Injury Solutions Inc (SPIN):企業の財務・戦略的SWOT分析
    Summary Spine Injury Solutions Inc (SPIN), formerly Spine Pain Management Inc is a medical service provider that provides medical technology and healthcare management solutions for liability spine injuries. The company provides services such as clinical management, and billing and collection of medi …
  • Sypris Solutions Inc (SYPR):企業の財務・戦略的SWOT分析
    Sypris Solutions Inc (SYPR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Kimbell Royalty Partners LP (KRP):石油・ガス:M&Aディール及び事業提携情報
    Summary Kimbell Royalty Partners LP (KRP), is an oil and gas company that owns and acquires mineral and royalty interests in oil and natural gas properties throughout the US. The company has interests in the Permian Basin, Eagle Ford, Bakken Shale, San Juan Basin, Mid-Continent, East Texas, Barnett …
  • Boone Electric Cooperative:企業の戦略的SWOT分析
    Boone Electric Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Linn Energy, LLC:企業の戦略・SWOT・財務情報
    Linn Energy, LLC - Strategy, SWOT and Corporate Finance Report Summary Linn Energy, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Dalton Pharma Services-製薬・医療分野:企業M&A・提携分析
    Summary Dalton Pharma Services (Dalton) is a contract manufacturing company that offers discovery, development and contract manufacturing services. The company’s product categories include building blocks, coelenterazines, drugs and metabolites, glitazones, gmp APIs, excipients and reagents, heteroc …
  • Eco (Atlantic) Oil & Gas Ltd (EOG):企業の財務・戦略的SWOT分析
    Summary Eco (Atlantic) Oil & Gas Ltd (Eco) is an oil and gas exploration and development company. The company’s business activities include acquisition, identification, and development of upstream petroleum projects across Africa. The company's projects include cooper license-PEL 030, Sharon license …
  • National Central Cooling Company:企業の戦略・SWOT・財務情報
    National Central Cooling Company - Strategy, SWOT and Corporate Finance Report Summary National Central Cooling Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • NSK Ltd.:企業の戦略・SWOT・財務分析
    NSK Ltd. - Strategy, SWOT and Corporate Finance Report Summary NSK Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Caterpillar Inc (CAT)-石油・ガス分野:企業M&A・提携分析
    Summary Caterpillar Inc. (Caterpillar) is a manufacturer of construction, transportation and energy equipment. It designs, manufactures, markets and sells construction and mining equipment, industrial gas turbines, forestry machinery, diesel and natural gas engines, and diesel-electric locomotives. …
  • Greencore Group Plc:戦略・SWOT・企業財務分析
    Greencore Group Plc - Strategy, SWOT and Corporate Finance Report Summary Greencore Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Nacional Financiera S.N.C.:企業の戦略・SWOT・財務情報
    Nacional Financiera S.N.C. - Strategy, SWOT and Corporate Finance Report Summary Nacional Financiera S.N.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Ube Industries Ltd (4208):企業の財務・戦略的SWOT分析
    Ube Industries Ltd (4208) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Qiagen Aarhus AS:企業の戦略的SWOT分析
    Qiagen Aarhus AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • OncoSil Medical Ltd (OSL):企業の財務・戦略的SWOT分析
    Summary OncoSil Medical Ltd (OncoSil), is a medical device company that develops and commercializes products for the treatment of pancreatic and liver cancer. The company’s lead product includes oncosil, a brachytherapy device that emits beta radiation and is implanted directly inside the cancerous …
  • Cabot Corp (CBT):企業の財務・戦略的SWOT分析
    Cabot Corp (CBT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Investment Technology Group, Inc.:企業の戦略・SWOT・財務情報
    Investment Technology Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Investment Technology Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • NanoViricides Inc (NNVC)-製薬・医療分野:企業M&A・提携分析
    Summary NanoViricides Inc (NanoViricides), formerly Edot-com.com Inc is a biopharmaceutical company that provides nanomedicine technology solutions. The company conducts research in the areas of medical science and pharmaceutical technology such as polymeric micelles, multi-specific multi-targeting, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆